GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Agenus Inc. (AGEN) [hlAlert]

Rating:
Buy AGEN
up 179.75 %

Agenus Inc. (AGEN) rated Buy with price target $6 by Global Hunter Securities

Posted on: Thursday,  Dec 1, 2011  9:25 AM ET by Global Hunter Securities

Global Hunter Securities rated Buy Agenus Inc. (NASDAQ: AGEN) on 12/01/2011, when the stock price was $2.47. Since
then, Agenus Inc. has gained 179.76% as of 01/21/2016's recent price of $6.91.
If you would have followed this Global Hunter Securities's recommendation on AGEN, you would have gained 179.75% of your investment in 1512 days.

Antigenics Inc. is engaged in the discovery and development of a family of novel immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight disease. The company is evaluating the lead immunotherapeutic, Oncophage, in six separate phase II or phase I/II clinical trials in four different cancers. The company is also developing immunotherapeutics to treat infectious diseases, such as genital herpes, and autoimmune disorders, such as diabetes and multiple sclerosis.

Global Hunter Securities uses a disciplined quantitative and qualitative approach, our analysts are focused on covering small-cap companies with unique value and above average growth, primarily in the following sectors: Consumer, Energy, Healthcare, Industrial, Services and Technology. Additionally, Global Hunter Securities has analysts specifically focused on Special Situations and International opportunities. Global Hunter Securities' analysts maintain strong relationships and ongoing dialogue with management teams and industry professionals to ensure propitious access to information.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/1/2011 9:25 AM Buy
None
2.47 6.00
as of 12/30/2011
1 Week down  -9.50 %
1 Month down  -19.02 %
3 Months   
1 YTD down  -19.02 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy